Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering, and Cantor is also serving as a book-running manager for t
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome CongressGlobeNewswire
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $7.00 to $6.00. They now have a "buy" rating on the stock.MarketBeat
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
TSHA
Earnings
- 8/12/24 - Beat
TSHA
Sec Filings
- 8/12/24 - Form 10-Q
- 8/12/24 - Form 8-K
- 7/5/24 - Form 144
- TSHA's page on the SEC website